EurekAlert! Cancer Research - News Releases

News Releases

Updates every hour. Last Updated: 7-Jul-2025 20:10 ET (8-Jul-2025 00:10 GMT/UTC)

Finnish researchers’ discovery may reveal why breast cancer is not always responsive to immunotherapy

University of Helsinki
Peer-Reviewed Publication

A Finnish discovery opens the door to more personalised cancer care. The research model is attracting global interest.

Journal: Nature Communications
Funder: Academy of Finland, Finnish Cancer Organization, Finnish Medical Foundation, Jane and Aatos Erkko Foundation, Biomedicum Helsinki Foundation, Eemil Aaltonen Foundation, Finnish Foundation for Technology Promotion, Business Finland, European Union’s Horizon 2020 Research and Innovation Programme

Does a culturally tailored quality of life intervention benefit Latina breast cancer survivors and caregivers?

Wiley
Peer-Reviewed Publication

A recent randomized controlled trial published by Wiley online in CANCER assessed the benefits of a group-based intervention that fosters communication and coping skills in a culturally tailored way for Latina breast cancer survivors and their caregivers.

Journal: Cancer

Sea change in cancer care requires urgent action to strengthen oncology workforce, care delivery

Canadian Medical Association Journal
Peer-Reviewed Publication

Rapid advances in cancer treatment have benefitted many people, but urgent change is needed in Canada’s cancer care workforce to ensure patient care, according to an analysis published in CMAJ (Canadian Medical Association Journal) https://www.cmaj.ca/lookup/doi/10.1503/cmaj.241425.

Journal: Canadian Medical Association Journal

Preventing chronic inflammation from turning into cancer

Charité - Universitätsmedizin Berlin
Peer-Reviewed Publication

Chronic inflammatory bowel disease is challenging to treat and carries a risk of complications, including the development of bowel cancer. Young people are particularly affected: when genetic predisposition and certain factors coincide, diseases such as ulcerative colitis or Crohn's disease usually manifest between the ages of 15 and 29 - a critical period for education and early career development. Prompt diagnosis and treatment are crucial. Researchers at Charité - Universitätsmedizin Berlin have now discovered a therapeutic target that significantly contributes to halting the ongoing inflammatory processes. Their findings are published in the current issue of the journal Nature Immunology*.

Journal: Nature Immunology

Immunotherapy boosts chemotherapy in combating stage 3 colon cancer

Mayo Clinic
Reports and Proceedings

New research led by Mayo Clinic Comprehensive Cancer Center found that adding immunotherapy to chemotherapy after surgery for patients with stage 3 (node-positive) colon cancer — and with a specific genetic makeup called deficient DNA mismatch repair (dMMR) — was associated with a 50% reduction in cancer recurrence and death compared to chemotherapy alone.

Meeting: 2025 ASCO Annual Meeting

Adding immune checkpoint inhibitor to standard chemotherapy regimen improves outcomes in stage 3 colon cancer, study finds

Dana-Farber Cancer Institute
Reports and Proceedings

Combining standard adjuvant chemotherapy with an immune checkpoint inhibitor (atezolizumab) leads to a significant improvement in disease-free survival in a subset of patients with stage 3 colon cancer that is deficient in DNA mismatch repair (dMMR), Dana-Farber Cancer Institute investigator Dr. Jeffrey Meyerhardt and his colleagues report at the 2025 American Society of Clinical Oncology (ASCO) meeting.

Meeting: 2025 ASCO Annual Meeting

Diet influences survival after stage iii colon cancer, Dana-Farber study finds

Dana-Farber Cancer Institute
Reports and Proceedings

Patients with colon cancer who consumed an anti-inflammatory diet during a phase 3 clinical trial showed longer overall survival post-treatment compared to those on a proinflammatory diet, according to a Dana-Farber Cancer Institute analysis. Engaging in higher levels of physical activity may amplify the positive influence on survival.

Meeting: 2025 ASCO Annual Meeting

Switch to experimental drug after liquid biopsy detection of breast cancer recurrence improves outcomes

Weill Cornell Medicine
Peer-Reviewed Publication

A large prospective, randomized clinical trial in patients with advanced breast cancer has found that the use of liquid biopsy blood tests for early detection of a treatment-resistance mutation, followed by a switch to a new type of treatment, substantially extends the period of tumor control compared to standard care.

Journal: New England Journal of Medicine

Alliance presents results from phase III ATOMIC trial combining atezolizumab with chemotherapy for patients with stage III dMMR colon cancer at ASCO 2025

Alliance for Clinical Trials in Oncology
Peer-Reviewed Publication

The Alliance for Clinical Trials in Oncology announced today results from ATOMIC (A021502), a phase III trial evaluating standard chemotherapy alone or combined with atezolizumab (Tecentriq^®) in treating patients who have surgically resected stage III colon cancer and deficient deoxyribonucleic acid (DNA) mismatch repair (dMMR). The study, sponsored by the National Cancer Institute (NCI) and conducted in partnership with Genentech, a member of the Roche Group, met its primary endpoint, demonstrating a statistically significant improvement in disease-free survival (DFS) with the addition of atezolizumab, an anti-PD-L1 monoclonal antibody, to standard adjuvant FOLFOX (5-fluorouracil, leucovorin, and oxaliplatin). The data are being presented today at 1:05 pm CDT/2:05 pm ET during the Plenary Session at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting (LBA1) by Alliance Study Chair Frank Sinicrope, MD.

Funder: NIH/National Cancer Institute
Meeting: 2025 ASCO Annual Meeting

Dual-target CAR T cell therapy slows growth of aggressive brain cancer

University of Pennsylvania School of Medicine
Peer-Reviewed Publication

A dual-target CAR T cell therapy approach shows promise for slowing tumor growth in a notoriously aggressive and fast-growing brain cancer.

Journal: Nature Medicine
Meeting: 2025 ASCO Annual Meeting

41
42
43
44
45